Summary: This study was designed to determine the ef fects of dexmedetomidine on CBP velocity as measured by transcranial Doppler sonography in human volunteers. Dexmedetomidine, a potent a-2 adrenergic agonist, was administered by computer-driven infusion pump to six male volunteers. Serial measurements of middle cerebral artery blood flow velocity at four steady-state plasma concentrations of dexmedetomidine were made with a 2-MHz transcranial Doppler transducer via the temporal window. The targeted plasma concentrations were 0.49, 0.65, 0.81, and 0.97 ng/ml. These represent 60, 80, 100, and 120%, respectively, of the mean peak concentration following the intramuscular administration of 2 fl-g/kg of dexmedetomidine. Subjects experienced a significant de gree of sedation at the highest infusion rates. Mean CBP velocity decreased with each increase in plasma concen tration of dexmedetomidine and then began to return to a-2 adrenergic agonists (e.g., xylazine and deto midine) have been extensively used in veterinary anesthesia. More recently, the analgesic-and anes thetic-sparing properties of the partial a-2 agonist, clonidine, have been documented in humans (Ghi gnone et ai., 1986; Flacke et ai., 1987; Engelman et ai., 1989; Bernard et al., 1989) . Dexmedetomidine is a potent and selective agonist of the a-2 adrenergic receptor and has been shown to possess hypnotic/ anesthetic properties in a variety of species (Doze et al., 1989; Segal et al., 1988; Scheinin et al., 1987; Received July 20, 1992 
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Previous studies have documented a 30-45% de crease in CBF following the administration of dexmedetomidine to halothane-and isoflurane anesthetized dogs (Karlsson et ai., 1990; Zornow et al., 1990) . This decrease in blood flow occurred without any associated decrease in the cerebral metabolic rate for oxygen. Because of concerns re garding the applicability of these findings to hu mans, the current study was conducted to examine the effects of hypnotic doses of dexmedetomidine on CBF velocity in human volunteers. Although it is not possible directly to compare blood flow rates with Doppler-derived blood flow velocities, previ ous studies have documented a good correlation be-tween changes in these measures of cerebral perfu sion (Kirkham et aI., 1986; Bishop et aI., 1986; Lindegaard et aI., 1987; Barzo et aI., 1991) .
METHODS
This study was approved by the Institutional Human Studies Committee, and informed consent was obtained from the six male subjects who agreed to participate. The subjects, ranging in age from 27 to 40 years, were fasted overnight and abstained from the use of alcohol and caf feine for 24 h before start of the study. Upon arrival in the operating room, intravenous and radial arterial catheters were inserted under local anesthesia. A 2-MHz transcra nial Doppler probe (Medasonics, Fremont, CA, U.S.A.), positioned over the temporal bone and the middle cere bral artery (MCA), was isonated at a depth of �50 cm. Continuously monitored variables included heart rate, ar terial blood pressure, oxygen saturation, and CBF veloc ity. Level of sedation (as assessed by a visual analogue scale), dexmedetomidine plasma concentrations, and ar terial blood gases were recorded intermittently. After col lection of two 30-min periods of baseline data, a com puter-driven infusion pump using a pharmacokinetic model of dexmedetomidine's distribution and elimination was used to produce four increasing steady-state plasma concentrations of the drug. Repeated measurements of the above variables were made at each plasma level which was maintained for 30 min before the step increase to the next higher concentration.
All tracings of MCA flow velocity were recorded on videotape and analyzed after completion of the study. Representative mean MCA flow rates for each volunteer were recorded at 10, 20, and 30 min after each step change in dexmedetomidine concentration. These were then averaged to yield a single value for each plasma concentration of dexmedetomidine which was used in subsequent statistical analysis. The corresponding pulsa tility index was calculated by dividing the difference be tween systolic and diastolic flow velocities by the mean velocity [P.1. = (systolic velocity -diastolic velocity)/ mean velocity]. After data collection at the highest plasma concentration (1.01 ng/mI), the dexmedetomidine infusion was discontinued and the subjects observed for an additional 2 h, at which time a final measurement of flow velocity was made.
Data were analyzed by repeated measures analysis of variance followed by paired t tests to compare the values obtained immediately before beginning the dexmedetomi dine infusion (B2; Fig. 1 ) with each of the subsequent periods. All values are mean ± SO; MAP, mean arterial pressure; BI and B2, baseline values before drug infusion; 01-04, the four steady-state levels of dexmedetomidine; Recovery, values ob tained � 2 h after completion of dexmedetomidine infusion; Oex, dexmedetomidine. a p < 0.05 vs. B2. drug infusion, CBF velocity returned to predrug levels ( Fig. 1) . Analysis of the pulsatility index re vealed increasing values which were statistically different from basal levels only at the 0.94-ng/ml (D3) concentration of dexmedetomidine (Fig. 2) . One factor which is known to alter CBF velocity is an alteration in arterial P aco2 (Markwalder et aI., 1984; Ringelstein et aI., 1988) . As expected, CBF velocity has been shown to increase with hypercap nia and decrease in the presence of hypocapnia. In the current study, the small increases in arterial car bon dioxide tension would have tended to increase flow velocity; hence the true effect of dexmedeto midine on blood flow velocity might have been found to be even greater than was observed in this study, had it been possible to maintain a constant carbon dioxide tension.
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Although the percent decrease in flow velocity seen in this study was not as great as decreases seen in previous animal studies using the venous outflow technique of measuring CBF, this is not surprising given the differences in doses of dexmedetomidine used in the various protocols. In the dog studies, dexmedetomidine was given as a 1 f,1g/kg bolus, which has been previously shown to produce nearly a surgical level of anesthesia (i.e., a 90% decrease in halothane requirement). In contrast, in the current study, even at the highest level of infusion, only 50% of the patients failed to respond to verbal com mands. the pulsatility index may be due to a variety of fac tors, including alterations in cardiac output, con tractility, and heart rate, the observed increase in the pulsatility index is consistent with an increase in cerebral vascular resistance due to a direct vaso constrictive effect of the drug.
